Table 4.

Random-intercept model predicting utilization of buprenorphine treatment over 24 months after 1^st follow-up (n=789)

Covariates	OR (95% CI)
	Model 1	Model 2
Intercept	1.18 (0.25, 5.67)	1.35 (0.28, 6.48)
Slope (months)	0.98 (0.97, 0.99)**	0.98 (0.97, 0.99)**
Interaction with intercept
Participant characteristics
Randomized to BUP (ref: MET)	1.55 (0.77, 3.15)	1.65 (0.81, 3.36)
Age (years)	0.97 (0.94, 1.01)	0.97 (0.94, 1.01)
Male (ref: female)	0.75 (0.36, 1.56)	0.78 (0.37, 1.65)
Race/ethnicity (ref: White)
Black	0.35 (0.08, 1.50)	0.33 (0.08, 1.40)
Hispanic	0.15 (0.04, 0.50)**	0.14 (0.04, 0.49)**
Other race	0.82 (0.17, 4.07)	0.78 (0.16, 3.85)
Less than high school education (ref: HS or more)	0.92 (0.37, 2.30)	0.96 (0.38, 2.43)
Cocaine positive at baseline (ref: negative)	0.70 (0.33, 1.50)	0.74 (0.35, 1.58)
Injection drug use (ref: no injection)	0.67 (0.33, 1.36)	0.57 (0.27, 1.19)
West coast site (ref: East coast)	0.29 (0.14, 0.60)***	0.29 (0.14, 0.61)***
Total no. of MET treatment received since 1st follow-up	0.81 (0.76, 0.85)***	0.81 (0.76, 0.85)***
Time-varying covariate
Incarceration since 1st follow-up	0.29 (0.15, 0.54)***	0.28 (0.15, 0.52)***
Participant experiences of buprenorphine treatment
BUP Accessibility	0.94 (0.73, 1.22)	1.06 (0.80, 1.40)
BUP Acceptability	4.57 (2.55, 8.18)***	7.11 (3.35, 15.10)***
Interaction term   BUP Accessibility × BUP Acceptability	--	1.51 (1.05, 2.18)*

BUP=buprenorphine; MET=methadone

^*p<0.05,

^**p<0.01,

^***p<0.001